Leukotriene receptor antagonist (LTRA)
Cysteinyl leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma, acute prevention of exercise-induced bronchoconstriction, and relief of seasonal and perennial allergic rhinitis symptoms (when alternatives are inadequate or not tolerated).
Also known as: Singulair, montelucaste sódico, montelukast sodium
DailyMed approved label (Montelukast Tablet; setID 583a9499-97f0-2ebf-e063-6394a90a35af).
DailyMed approved label (Montelukast Tablet; setID 583a9499-97f0-2ebf-e063-6394a90a35af).
No documented drug–drug interactions for this medicine.
Montelukast should be taken without food; meals may reduce the absorption of the tablet.
Take 1 hour before or 2 hours after meals.
EMC-UK (MHRA) — approved Montelukast SmPC: https://www.medicines.org.uk/emc/product/1222/smpc
Montelukast is hepatically metabolised; use with caution in liver disease.
Monitor liver function in patients with liver disease.
EMC-UK (MHRA) — approved Montelukast SmPC: https://www.medicines.org.uk/emc/product/1222/smpc
Data on montelukast in pregnancy are limited; use only if the benefit outweighs the risk.
Can be used if asthma is not controlled with ICS alone.
Excreted into breast milk in small amounts; probably compatible.
No specific additional contraception.
EMC-UK (MHRA) — approved Montelukast SmPC: https://www.medicines.org.uk/emc/product/1222/smpc
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Oral selective CysLT1 receptor antagonist: blocks the effects of cysteinyl leukotrienes (LTC4, LTD4, LTE4) in the airways and nasal mucosa, reducing edema, smooth-muscle contraction and inflammatory activity associated with asthma and allergic rhinitis.
High-affinity, selective binding to the CysLT1 receptor of cysteinyl leukotrienes (in preference to other pharmacologically important receptors).
Oral bioavailability of 64% after a 10 mg tablet; plasma peaks at 3–4 hours; plasma protein binding > 99%.
Extensively metabolized (CYP3A4, CYP2C8 and CYP2C9); metabolites are excreted almost exclusively in bile.
Half-life of 2.7–5.5 hours (in healthy adults).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
